On the 18th, Rocket Healthcare held an initial public offering (IPO) press conference in Yeouido, Seoul and announced its growth strategy after listing on KOSDAQ.
The total number of shares offered by Rocket Healthcare is 1.56 million, the desired offering price per share is 11,000 won to 13,000 won, and the total offering amount is 17.2 billion won to 20.3 billion won. After confirming the offering price by conducting demand forecast for institutional investors from April 14 to 18, subscription for general investors will be conducted for two days on the 23rd and 24th of the same month. It is scheduled to enter the KOSDAQ market on May 12, and the lead manager is SK Securities.
Founded in 2012, Rocket Healthcare is a specialized company in hyper-personalized customized organ regeneration platforms based on artificial intelligence (AI). They have successfully commercialized the world’s first organ regeneration platform by developing technologies that automatically model the affected area by incorporating artificial intelligence (AI), a medical 3D bio-printer that produces customized patches, and a hyper-personalized bioink production kit.
The first market that Rocket Healthcare entered with this long-term regeneration platform was the skin regeneration field. Among these, the focus was on the treatment of 'diabetic foot', a foot ulcer that can be caused by diabetes, a chronic disease.
Rocket Healthcare conducted domestic and international medical clinical trials to prove the effectiveness of its AI hyper-personalized organ regeneration platform, and the company announced that it secured an 82.1% cure rate with just one treatment after five clinical trials. It also explained that it is expected that the financial contribution will increase as the cost will be reduced by about a quarter compared to existing treatment methods such as skin grafting.
In addition, Rocket Healthcare has established a technological entry barrier by publishing 16 papers and registering and applying for 165 patents domestically and internationally, and based on this technological prowess, it received an A grade from both evaluation agencies in the technology evaluation for KOSDAQ technology special listing.
Along with the validation of the skin regeneration platform, Rocket Healthcare has obtained global certifications from 16 countries, including the European CE MDR and the US FDA, in order to enter overseas markets. It has currently signed commercialization contracts with global partners in 46 countries and is selling in North America, the Middle East, Asia, South America, and Europe.
As the organ regeneration platform owned by Rocket Healthcare has the potential to be applied to cartilage, kidney, etc. in addition to skin, the company plans to expand the regenerative treatment market by broadening the scope of application from the existing diabetic foot to skin cancer, burns, cartilage, and kidney. The cartilage regeneration platform has currently completed preclinical and clinical trials, and the kidney regeneration platform is planning preliminary clinical trials.
“As the world enters a super-aging society, I believe the importance of ‘hyper-personalized regeneration’ capabilities in chronic disease treatment will be increasingly emphasized,” said Yoo Seok-hwan, CEO of Rocket Healthcare. “I believe it is very significant that we have commercialized the world’s first organ regeneration platform that combines AI and biotechnology in the medical market and that there is a real therapeutic effect through the creation of a personalized regeneration environment.”
He added, “In the future, we will expand sales of our skin regeneration platform and enter the cartilage and kidney markets to resolve the inefficiencies in the existing chronic disease treatment market and leap forward as a global first mover leading medical innovation with AI hyper-personalized organ regeneration.”
The funds raised through the listing will be used for global marketing expenses for expansion into Europe and South America, confirmatory clinical trials for expansion of the cartilage regeneration platform, and clinical trials for the kidney regeneration platform.
- See more related articles
You must be logged in to post a comment.